Contrave | 1201668-08-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 菲及其衍生物
• 英文名称: Contrave
• 英文别名: (4R,4aS,7aR,12bS)-3-(cyclopropylmethyl)-4a,9-dihydroxy-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one;2-(tert-butylamino)-1-(3-chlorophenyl)propan-1-one
• CAS: 1201668-08-7
• 化学式: C33H41ClN2O5
• 分子量: 581.1
• InChiKey: KVNBDVQGENTICK-ITLPAZOVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.82
• 重原子数：
  41
• 可旋转键数：
  6
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.58
• 拓扑面积：
  99.1
• 氢给体数：
  3
• 氢受体数：
  7

文献信息

• PYRROLIDINONE DERIVATIVES AS GPR119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS
  申请人：SCHWINK Lothar

  公开号：US20140099333A1

  公开（公告）日：2014-04-10

  The present invention relates to pyrrolidinone derivatives. The pyrrolidinone derivatives are GPR119 modulators and useful for the prevention and/or treatment of diabetes, obesity, dyslipidemia and related disorders. The invention furthermore relates to the use of pyrrolidinone derivatives as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.

  本发明涉及吡咯烷酮衍生物。这些吡咯烷酮衍生物是GPR119调节剂，适用于预防和/或治疗糖尿病、肥胖、血脂异常及相关疾病。此外，本发明还涉及将吡咯烷酮衍生物用作药物中的活性成分，以及包含它们的药物组合物。
• Systems and methods for monitoring medication effectiveness
  申请人：Cloud DX, Inc.

  公开号：US10463299B1

  公开（公告）日：2019-11-05

  System for determining the effectiveness of various prescribed medications. Here a variety of different types of patient pulse wave measurements (e.g. blood pressure, pulse oximeter, ECG) and other physiological measurements are obtained. This actual data is compared to calculated measurements that would be expected based on the various patient baseline measurements in the absence of medication, schedule of medications, and impact of medications the various patient baseline measurements. If the actual data meets expectations, then the medication is likely acting as anticipated. Depending on which types of data do not meet expectations, problems with one or more previously described medications may be reported. Other types of patient physiological readings, such as temperature, motion, lung function, brain wave function (EEG) and the like may also be obtained, and these additional types of readings can be used to extend the range of different types of drugs/medications that the system can successfully monitor.

  用于确定各种处方药疗效的系统。在这里，可以获得各种不同类型的病人脉搏波测量值（如血压、脉搏血氧计、心电图）和其他生理测量值。将这些实际数据与计算得出的测量值进行比较，这些测量值是在没有用药、用药时间安排和用药对各种病人基线测量值的影响的情况下，根据各种病人基线测量值预计得出的。如果实际数据符合预期，则说明药物的作用可能与预期相符。根据哪些类型的数据不符合预期，可能会报告一种或多种先前描述的药物存在问题。还可以获得其他类型的患者生理读数，如体温、运动、肺功能、脑电波功能（EEG）等，这些额外类型的读数可用于扩大系统可成功监控的不同类型药物/疗法的范围。
• US8853412B2
  申请人：——

  公开号：US8853412B2

  公开（公告）日：2014-10-07